Details of the Drug

General Information of Drug (ID: DMAKXW9)

Drug Name
PLEGRIDY
Synonyms Peginterferon beta-1a
Indication
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Approved [1]
Sequence
>Sequence
MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIY
EMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSL
HLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 34.8 mcgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 280 ng/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1-1.5 days [2]
Clearance
The clearance of drug is 4.1 L/h [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 78 hours [4]
Metabolism
The drug is metabolized via the liver [3]
Vd
The volume of distribution (Vd) of drug is 481 L [3]
Cross-matching ID
TTD ID
D0LW4O

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interferon-beta (IFNB1) TT4TZ8J IFNB_HUMAN Modulator [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7637).
2 Hu X, Cui Y, White J, Zhu Y, Deykin A, Nestorov I, Hung S: Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. Br J Clin Pharmacol. 2015 Mar;79(3):514-22. doi: 10.1111/bcp.12521.
3 FDA Approved Drug Products: PLEGRIDY (peginterferon beta-1a) injection, for subcutaneous or intramuscular use
4 Product monograph: Avonex (interferon beta-1a) injection
5 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.